Posted on 09/24/2022 7:41:05 AM PDT by ConservativeMind
Researchers identified critical genomic changes in response to abiraterone acetate/prednisone, a standard treatment option for men with progressive, incurable and castration-resistant prostate cancer.
"We defined a potential strategy for both responders and nonresponders of the drug that may help men overcome resistance and prolong survival," says Liewei Wang, M.D., Ph.D.
Dr. Wang explains that while several drug choices are available to control disease progression, many questions remain over which drugs to use in individual cases. Also, predictive biomarkers for drug resistance and sensitivity remain primarily unknown.
Abiraterone acetate is a standard treatment option for men with castration-resistant prostate cancer. However, the response is limited, no known biomarkers predict prognosis, and alternative therapies for those who failed treatment are unavailable.
In the Prostate Cancer Medically Optimized Genome Enhanced Therapy study, also known as PROMOTE, researchers revealed DNA sequences associated with response to abiraterone acetate to identify additional treatment options for men with advanced prostate cancer resistant to all standard therapies.
They identified an 11-gene drug panel that provided a new tool to individualize treatment for abiraterone acetate. A genetic testing panel is a laboratory test that looks at a select group of genes. The 11-gene panel predicted a worse prognosis for a subset of primary or metastatic patients enrolled in the study.
The researchers analyzed whole-exome sequencing and RNA sequence data from 83 patients with metastatic biopsies before and after 12 weeks of abiraterone acetate/prednisone treatment. They identified genomic alterations associated with acquired resistance after 12 weeks of this treatment.
"We analyzed the posttreatment genomic landscape of metastatic biopsies in these patients with metastatic castration-resistant prostate cancer to identify mechanisms of acquired resistance," says Hugues Sicotte, Ph.D.. "These results may assist with selecting alternative therapies in a subset of abiraterone acetate-resistant patients with the highest risk of having the poorest outcome."
(Excerpt) Read more at medicalxpress.com ...
From the abstract:
Implications: Finally, we identified candidates drugs to reverse AA/P resistance : topoisomerase inhibitors and drugs targeting the cell cycle via the MYC/AURKA/AURKB/TOP2A and/or PI3K/AKT1/MTOR pathways.
I’m turning 60 next month and got tested for the first time for prostate cancer in August, also got a colonoscopy both negative thank God because both cancers run in my family. My granddad died of colon cancers and my uncle - my dads brother - died of prostate. Why I waited so long was absolutely insane and irresponsible.
“castration-resistant prostate cancer”
I think we may need a mangled genitals ping?
Put this in your search bar and spend some time reading the clinical trials: nih.gov Ivermectin Cancer.
Wait a minute, isn’t that the drug the DemoMarxist domestic enemies of the USA tried to ban to ensure maximum deaths by Covid?
Disclaimer: Opinions posted on Free Republic are those of the individual posters and do not necessarily represent the opinion of Free Republic or its management. All materials posted herein are protected by copyright law and the exemption for fair use of copyrighted works.